Bavarian Nordic (CPSE:BAVA) Q1 Margin Squeeze Challenges Bullish Profitability Narrative

Bavarian Nordic (CPSE:BAVA) has opened 2026 with Q1 revenue of DKK 1,057.8 million and Basic EPS of DKK 0.20, while the trailing twelve months show revenue of DKK 5.96 billion and Basic EPS of DKK 14.86. This sets a clear snapshot of the current run rate. Over recent quarters, revenue has moved from DKK 2,093.9 million in Q4 2024 to DKK 1,346.6 million in Q1 2025 and DKK 1,057.8 million in Q1 2026. Basic EPS shifted from DKK 10.15 to DKK 2.70 and then DKK 0.20. The latest release therefore puts the spotlight firmly on how margins are holding up against that backdrop.

See our full analysis for Bavarian Nordic.

With the headline numbers on the table, the next step is to set these results against the prevailing narratives around Bavarian Nordic's growth, risks, and profitability to see which stories line up and which start to look out of date.

See what the community is saying about Bavarian Nordic

Net profit margin slips to 19.7%

• Over the last 12 months, Bavarian Nordic reported a net profit margin of 19.7%, compared with 21.2% a year earlier, on trailing revenue of DKK 5.96b and net income of DKK 1.17b.
• Bulls see long term margin strength as a key part of the story, yet this 1.5 percentage point margin compression and the Q1 2026 net income of DKK 16.9 million against DKK 1,057.8 million of revenue underline how sensitive profitability is to mix and volume:
• Consensus bullish arguments lean on higher gross margins from manufacturing changes and travel health growth, but the most recent quarter shows earnings much thinner than the trailing 12 month picture.
• That gap between quarterly profit and trailing margin makes it important to separate sustainable operating margin from periods of very strong demand or contract timing when weighing the bullish case.

Bulls point to manufacturing gains and travel vaccines as a margin story, but these Q1 figures show how quickly profitability can tighten, so it is worth seeing how the full bull case fits with the current run rate. 🐂 Bavarian Nordic Bull Case

One off DKK 748.1m gain distorts trailing EPS

• The trailing 12 month earnings include a one off gain of DKK 748.1 million, which is large relative to trailing net income of DKK 1,173.6 million and Basic EPS of DKK 14.86.
• Critics highlight that recent earnings growth over five years, at 57.9% per year, looks much less robust once this single gain and the most recent year on year earnings decline are factored in:
• The bearish view argues that heavy R&D spend and product concentration could pressure margins, and the reliance on a one off gain inside the trailing numbers supports that caution when you compare it with the modest Q1 2026 EPS of DKK 0.20.
• With earnings for Q4 2025 showing a loss on Basic EPS of DKK 4.16 despite revenue of DKK 1,450.9 million, the bears’ concern about earnings volatility is clearly reflected in the recent quarterly pattern.

Skeptics warn that when a big one off item and choppy quarterly profits are doing so much of the work, investors need to focus on what underlying earnings look like without those boosts. 🐻 Bavarian Nordic Bear Case

P/E of 12.3x versus analysts’ DKK 271.67 target

• The stock trades on a P/E of 12.3x, below the European Biotechs average of 15.1x and peer average of 16.2x, while the current share price of DKK 188.30 sits well under both the analyst price target of DKK 271.67 and the DCF fair value of DKK 504.87.
• Consensus narrative points to a business that is highly reliant on a narrow vaccine mix and facing potential margin pressure, which sits awkwardly alongside a valuation picture that appears inexpensive on both multiples and DCF:
• On one side, five year profit growth of 57.9% per year and the margin profile support the idea that the current P/E discount and gap to DKK 271.67 could be compensating investors for those risks.
• On the other, the fall in trailing earnings over the most recent year and the lower 19.7% net margin suggest the discount might also be reflecting concerns that future profitability could be lower than the past trend.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Bavarian Nordic on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of bullish and bearish angles around Bavarian Nordic is clear. Take a moment to weigh the data yourself and decide where you stand with the 4 key rewards and 1 important warning sign

See What Else Is Out There

Recent results highlight thinner Q1 profitability, a slip in net margin to 19.7%, and earnings flattered by a sizeable one off gain.

If that mix of earnings volatility and reliance on special items leaves you wanting steadier prospects, compare it with the 302 resilient stocks with low risk scores to see what more resilient options look like right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.